Table 5.
Prognostic value of miRNAs in HBV-related HCC.
| Sample | miRNA panels |
Risk/protective factor |
HR/RR | CI | P-value | Outcome | References | ||
|---|---|---|---|---|---|---|---|---|---|
| Type | Size of case | Underlying cirrhosis, % | |||||||
| P/S | 97 HCC (60 HBV) | 32.0% (31/97) | miR-21 | Risk | 2.229 | 1.328–3.743 | 0.002 | OS | (47) |
| P/S | 136 HCC (129 HBV) | NA | miR-200a | Risk | 1.75 | 1.45–2.11 | <0.001 | OS | (125) |
| P/S | 62 HCC (40 HBV) | NA | miR-1246 | Risk | 10.24 | 1.39–75.67 | 0.023 | OS | (126) |
| P/S | 62 HCC (40 HBV) | NA | miR-1246 | Risk | 10.12 | 1.45–70.47 | 0.020 | DFS | (126) |
| P/S | 120 HBV-HCC | 85.8% (103/120) | miR-26a | Protective | 0.29 | 0.11–0.76 | 0.011 | LT-free survival | (127) |
| P/S | 120 HBV-HCC | 85.8% (103/120) | miR-29a | Protective | 0.36 | 0.15–0.91 | 0.030 | LT-free survival | (127) |
| Exosome | 128 HCC (121 HBV) | 76% (97/128) | miR-125b | Protective | 0.36 | 0.18–0.74 | 0.005 | OS | (40) |
| T | 148 HCC (82 HBV) | 41% (45/109) | miR-21 | Risk | NA | 1.19–1.47 | 0.004 | DFS | (21) |
| T | 140 HBV-HCC | NA | miR-21 | Risk | 1.509 | 1.079–2.112 | 0.016 | 3-years OS | (128) |
| T | 108 HBV-HCC | NA | miR-21 | Risk | 1.416 | 1.057–1.897 | 0.020 | 5-years OS | (128) |
| T | 115 HCC (101 HBV) | 51% (59/115) | miR-221 | Risk | 2.09 | 1.09–4.04 | 0.027 | MFS | (20) |
| T | 135 HCC (96 HBV) | 95% (128/135) | miR-221 | Risk | 2.846 | 1.564–5.181 | 0.001 | DFS | (25) |
| T | 135 HCC (96 HBV) | 95% (128/135) | miR-221 | Risk | 2.969 | 1.629–5.408 | <0.001 | OS | (25) |
| T | 166 HCC (146 HBV) | 84% (139/166) | 20-miRNA prognostic signature* | Risk | 2.75 | 1.58–4.79 | <0.001 | OS | (129) |
| T | 214 HBV-HCC | 93% (199/214) | 20-miRNA metastasis signature# | Risk | 2.1 | 1.2–3.6 | 0.01 | OS | (32) |
| T | 455 HCC (412 HBV) | 88% (400/455) | miR-26a | Protective | 0.48 | 0.21–1.0 | 0.05 | OS | (27) |
| T | 455 HCC (412 HBV) | 88% (400/455) | miR-26b | Protective | 0.48 | 0.20–0.91 | 0.04 | OS | (27) |
| T | 142 HCC (103 HBV) | 58% (82/142) | miR-122 | Protective | NA | NA | 0.001 | OS | (31) |
| T | 120 HCC (97 HBV) | 78% (93/120) | miR-200a | Protective | 0.382 | 0.215–0.896 | 0.004 | OS | (33) |
| T | 101 HCC (71 HBV) | NA | miR-200a | Protective | 0.403 | 0.242–0.670 | <0.001 | OS | (34) |
| T | 66 HCC (64 HBV) | NA | miR-203 | Protective | 0.202 | 0.064–0.638 | 0.006 | RFS | (130) |
| T | 66 HCC (64 HBV) | NA | miR-203 | Protective | 0.332 | 0.139–0.793 | 0.013 | OS | (130) |
*
miR-708, miR-34c-3p, miR-584, miR-4310, miR-744, miR-141, let-7d, miR-15a, miR-142-3p, miR-10b, let-7e, miR-28-3p, miR-193b, miR-101, miR-451, miR-142-5p, miR-26b, miR-497, miR-29c, miR-140-3p.
#
miR-338, miR-219-1, miR-207, miR-185, miR-30c-1, miR-1-2, miR-34a, miR-19a, miR-148a, miR-124a-2, miR-9-2, miR-148b, miR-122a, miR-125b-2, miR-194, miR-30a, miR-126, let-7g, miR-15a, miR-30e.
CI, confidence interval; DFS, disease-free survival; HBV, Hepatitis B virus; HR, hazard ratio; HCC, hepatocellular carcinoma; LT, liver transplantation; MFS, metastasis-free survival; OS, overall survival; P/S, plasma or serum; Ref, reference; RFS, recurrence-free survival; RR, relative risk; T, tissue.